Neogen expects Genomics sale review to end early 2027

The transaction remains subject to customary closing conditions and regulatory approvals, with regulatory review expected to conclude in early 2027.

Available on EDGAR 11/04/2026 - 04:01 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Neogen Corporation has a definitive agreement to sell its global Genomics business to Zoetis Inc., announced March 2, 2026. The transaction is subject to customary closing conditions and regulatory approvals.

Neogen and Zoetis continue cooperating with the Australian Competition and Consumer Commission and the New Zealand Commerce Commission in their reviews. Zoetis recently offered to divest certain assets in Australia, and Neogen expects regulatory review to conclude in early 2027.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

definitive agreement, customary closing conditions, regulatory approvals

3 terms

definitive agreement technical

"entered into a definitive agreement to sell"

A definitive agreement is a formal, legally binding document that outlines the final terms and conditions of a deal or transaction, such as a sale or partnership. It acts like a detailed contract that confirms all parties have agreed on the key details, making the deal official. For investors, it signals that the agreement is settled and moving toward completion, providing clarity and security about the transaction.

customary closing conditions technical

"subject to customary closing conditions"

"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

regulatory approvals regulatory

"and regulatory approvals"

Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is regulatory review of NEOG's Genomics sale expected to conclude?

Neogen expects regulatory review to conclude in early 2027. Zoetis recently offered to divest certain assets in Australia.

Which regulators are reviewing NEOG's Genomics sale?

The Australian Competition and Consumer Commission and the New Zealand Commerce Commission are reviewing the transaction. Neogen and Zoetis continue to cooperate with both agencies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000071137700007113772026-11-042026-11-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 04, 2026

Neogen Corporation

(Exact name of Registrant as Specified in Its Charter)

Michigan			0-17988	38-2367843
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
620 Lesher Place
Lansing, Michigan				48912
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (517) 372-9200

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.16 par value per share		NEOG		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 2, 2026, Neogen Corporation (“Neogen”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“Zoetis”). This transaction is subject to customary closing conditions and regulatory approvals. Both parties continue to cooperate with the Australian Competition and Consumer Commission (the “ACCC”) and the New Zealand Commerce Commission (the “NZCC”) in their ongoing reviews of the transaction. In order to assist the regulatory clearance process Zoetis has recently offered to divest certain assets in Australia, and as a result we expect regulatory review to conclude in early 2027.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEOGEN CORPORATION
Date:	November 4, 2026	By:	/s/ R. Bryan Riggsbee
			Name: R. Bryan Riggsbee Title: Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.4 KB